HK1036223A1 - Inhibition of xenoreactive antibodies - Google Patents
Inhibition of xenoreactive antibodiesInfo
- Publication number
- HK1036223A1 HK1036223A1 HK01106879A HK01106879A HK1036223A1 HK 1036223 A1 HK1036223 A1 HK 1036223A1 HK 01106879 A HK01106879 A HK 01106879A HK 01106879 A HK01106879 A HK 01106879A HK 1036223 A1 HK1036223 A1 HK 1036223A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- xenoantigen
- xenopolymer
- antibodies
- host
- xenograft
- Prior art date
Links
- 230000005764 inhibitory process Effects 0.000 title 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- PFAXACNYGZVKMX-UHFFFAOYSA-N fenethazine Chemical compound C1=CC=C2N(CCN(C)C)C3=CC=CC=C3SC2=C1 PFAXACNYGZVKMX-UHFFFAOYSA-N 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6052598A | 1998-04-15 | 1998-04-15 | |
PCT/US1999/008326 WO1999052561A1 (en) | 1998-04-15 | 1999-04-15 | Inhibition of xenoreactive antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1036223A1 true HK1036223A1 (en) | 2001-12-28 |
Family
ID=22030043
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK01106879A HK1036223A1 (en) | 1998-04-15 | 2001-09-28 | Inhibition of xenoreactive antibodies |
Country Status (10)
Country | Link |
---|---|
US (3) | US6572867B1 (de) |
EP (1) | EP1087791B1 (de) |
JP (1) | JP2002511431A (de) |
AT (1) | ATE304865T1 (de) |
AU (1) | AU761831B2 (de) |
CA (1) | CA2326618A1 (de) |
DE (2) | DE1087791T1 (de) |
ES (1) | ES2249890T3 (de) |
HK (1) | HK1036223A1 (de) |
WO (1) | WO1999052561A1 (de) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6399578B1 (en) | 1998-12-09 | 2002-06-04 | La Jolla Pharmaceutical Company | Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same |
JP2002531531A (ja) * | 1998-12-09 | 2002-09-24 | ラ ホヤ ファーマシューティカル カンパニー | 循環している抗体を減少させるための方法および処方物 |
WO2001051499A1 (en) * | 2000-01-13 | 2001-07-19 | Alchemia Pty Ltd | METHODS FOR SYNTHESIS OF α-D-GAL (1→3) GAL-CONTAINING OLIGOSACCHARIDES |
US7270961B2 (en) * | 2002-04-16 | 2007-09-18 | Hui Sunny Chang | In vitro assay for quantitating secreted antibodies in lymphocyte supernatant for evaluation of vaccine or antigen induced specific antibody secretion from ex vivo circulating antibody-secreting lymphocytes |
CA2583666A1 (en) * | 2004-10-13 | 2006-04-27 | Ilypsa, Inc. | Pharmaceutical compositions comprising a toxin-binding oligosaccharide and a polymeric particle |
US20060078534A1 (en) * | 2004-10-13 | 2006-04-13 | Dominique Charmot | Toxin binding compositions |
FR2886298A1 (fr) * | 2005-05-24 | 2006-12-01 | Ifremer | Anticorps ou fragment d'anticorps couple a un agent immunogene |
US8450068B2 (en) | 2007-02-16 | 2013-05-28 | University Of Virginia Patent Foundation | IgE antibodies to chimeric or humanized IgG therapeutic monoclonal antibodies as a screening test for anaphylaxis |
EP2095829A1 (de) | 2008-02-27 | 2009-09-02 | LEK Pharmaceuticals D.D. | Selenhaltige Modifizierungsmittel und Konjugate |
US9891219B2 (en) * | 2008-10-10 | 2018-02-13 | Mayo Foundation For Medical Education And Research | Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive |
US9420770B2 (en) | 2009-12-01 | 2016-08-23 | Indiana University Research & Technology Corporation | Methods of modulating thrombocytopenia and modified transgenic pigs |
US9642899B2 (en) | 2010-05-06 | 2017-05-09 | Mayo Foundation For Medical Education And Research | Implantation of a cardiac xenograft from a B4GALNT2KO and GTKO transgenic pig to reduce immunogenicity |
US20130149331A1 (en) * | 2011-05-03 | 2013-06-13 | Peng George Wang | Rhamnose and forssman conjugated immunogenic agents |
US9533214B2 (en) | 2012-09-25 | 2017-01-03 | Igt | Gaming system and method for providing plays of multiple games |
CN106103461B (zh) | 2014-03-13 | 2019-05-10 | 巴塞尔大学 | 结合抗髓鞘相关糖蛋白的IgM抗体的碳水化合物配体 |
EP2987503A1 (de) * | 2014-08-22 | 2016-02-24 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Verfahren und Reagenzien zur Prävention und/oder Behandlung von Infektionen |
WO2016065046A1 (en) | 2014-10-22 | 2016-04-28 | Indiana University Research & Technology Corporation | Triple transgenic pigs suitable for xenograft |
US11091591B2 (en) | 2015-09-16 | 2021-08-17 | Universität Basel | Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8001748L (sv) * | 1980-03-05 | 1981-09-06 | Kaellenius Gunilla | Kompositioner for terapeutisk eller diagnostisk anvendning jemte forfarande for terapeutik |
US5126131A (en) * | 1983-01-24 | 1992-06-30 | The Johns Hopkins University | Therapeutic suppression of specific immune responses by administration of antigen-competitive conjugates. |
US5268454A (en) * | 1991-02-08 | 1993-12-07 | La Jolla Pharmaceutical Company | Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier |
US5219564A (en) * | 1990-07-06 | 1993-06-15 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
US5191066A (en) * | 1990-12-07 | 1993-03-02 | Abbott Laboratories | Site-specific conjugation of immunoglobulins and detectable labels |
ATE232730T1 (de) | 1991-08-23 | 2003-03-15 | Alberta Res Council | Verfahren und zusammensetzungen zur verhinderung der antikörper-vermittelten abstossung von xenogenen transplantaten |
GB9202219D0 (en) * | 1992-02-03 | 1992-03-18 | Connaught Lab | A synthetic heamophilus influenzae conjugate vaccine |
US5879675A (en) * | 1994-03-15 | 1999-03-09 | Medical College Of Pennsylvania And Hahnemann University | Compositions and methods for vaccines comprising α-galactosyl epitopes |
US5866135A (en) * | 1994-04-21 | 1999-02-02 | North American Vaccine, Inc. | Group A streptococcal polysaccharide immunogenic compositions and methods |
CA2240941A1 (en) * | 1995-12-21 | 1997-07-03 | Procur Ab | Galactopyranosides and their use |
JP2001518074A (ja) * | 1997-02-05 | 2001-10-09 | バイオトランスプラント インク. | B細胞の免疫寛容誘導 |
US6676946B2 (en) * | 1997-03-27 | 2004-01-13 | Institut Pasteur | Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof |
JP3474583B2 (ja) * | 1997-04-18 | 2003-12-08 | ノバルティス アクチエンゲゼルシャフト | 新規糖タンパク質 |
US6096725A (en) | 1997-07-02 | 2000-08-01 | Neose Technologies, Inc. | Methods of using αGal oligosaccharides as immune system targeting agents |
-
1999
- 1999-04-15 DE DE1087791T patent/DE1087791T1/de active Pending
- 1999-04-15 ES ES99917553T patent/ES2249890T3/es not_active Expired - Lifetime
- 1999-04-15 US US09/292,153 patent/US6572867B1/en not_active Expired - Fee Related
- 1999-04-15 DE DE69927369T patent/DE69927369T2/de not_active Expired - Fee Related
- 1999-04-15 EP EP99917553A patent/EP1087791B1/de not_active Expired - Lifetime
- 1999-04-15 WO PCT/US1999/008326 patent/WO1999052561A1/en active IP Right Grant
- 1999-04-15 JP JP2000543171A patent/JP2002511431A/ja active Pending
- 1999-04-15 AU AU35645/99A patent/AU761831B2/en not_active Ceased
- 1999-04-15 AT AT99917553T patent/ATE304865T1/de not_active IP Right Cessation
- 1999-04-15 CA CA002326618A patent/CA2326618A1/en not_active Abandoned
-
2001
- 2001-09-28 HK HK01106879A patent/HK1036223A1/xx not_active IP Right Cessation
-
2003
- 2003-03-28 US US10/402,845 patent/US20040141944A1/en not_active Abandoned
-
2007
- 2007-10-31 US US11/932,737 patent/US20080124396A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1087791A1 (de) | 2001-04-04 |
DE69927369D1 (de) | 2006-02-02 |
EP1087791B1 (de) | 2005-09-21 |
CA2326618A1 (en) | 1999-10-21 |
ES2249890T3 (es) | 2006-04-01 |
US20080124396A1 (en) | 2008-05-29 |
DE69927369T2 (de) | 2006-06-22 |
DE1087791T1 (de) | 2002-02-21 |
WO1999052561A1 (en) | 1999-10-21 |
ATE304865T1 (de) | 2005-10-15 |
AU761831B2 (en) | 2003-06-12 |
US20040141944A1 (en) | 2004-07-22 |
AU3564599A (en) | 1999-11-01 |
US6572867B1 (en) | 2003-06-03 |
JP2002511431A (ja) | 2002-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1036223A1 (en) | Inhibition of xenoreactive antibodies | |
Setiady et al. | In vivo depletion of CD4+ FOXP3+ Treg cells by the PC61 anti‐CD25 monoclonal antibody is mediated by FcγRIII+ phagocytes | |
Zurier et al. | Prostaglandin E1 treatment of NZB/NZW F1 hybrid mice | |
MXPA03004793A (es) | Roedores transgenicos transcromosomales para elaborar anticuerpos humnanos. | |
MD1444B2 (ro) | Metode de inducere a toleranţei celulelor T faţă de un transplant de organe sau ţesuturi | |
HK1030625A1 (en) | Methods and compositions for immunomodulation | |
EP1220611A4 (de) | Suppressorzellen zur prävention und behandlung von immunantworten bei transplantationen | |
EA199901046A1 (ru) | Применение блокатора связывания cd40:cd154 для предотвращения противоадаптивных иммунных реакций, в частности отторжения трансплантанта | |
EP0700297A4 (de) | Die erzeugung von toleranz gegen fremdtransplantaten durch tolerogenese mit hilfe von ersatzlebewesen | |
HK1025738A1 (en) | Lo-cd2a antibody and uses thereof for inhibiting tcell activation and proliferation | |
HU9403006D0 (en) | Suppression of proliferative response and induction of tolerance wita polymorphil class ii.mal allopeptides | |
Wang et al. | Interleukin‐10 induces macrophage apoptosis and expression of CD16 (FcγRIII) whose engagement blocks the cell death programme and facilitates differentiation | |
DE69333448D1 (en) | P53 impfstoff | |
WO2000006194A3 (en) | Depletion of cells responsible for antibody-mediated graft rejection | |
WO1992021724A3 (de) | Unter abspaltung von alkoholen zu elastomeren vernetzbare organo(poly)siloxanmassen | |
Turcotte et al. | Mechanisms of action of Mycobacterium bovis BCG-induced suppressor cells in mitogen-induced blastogenesis | |
WO2002020619A3 (en) | HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3) | |
Cosenza et al. | Cell Interactions in Antibody Formation in Vitro: I. Role of the Third Cell in the in Vitro Response of Spleen Cells to Erythrocyte Antigens | |
WO1993006852A3 (en) | Methods of improving allograft or xenograft tolerance by administration of an lfa-3 or cd2 binding protein | |
EP0782630A4 (de) | Nierenpolycystose-gen | |
OBERHOLZER et al. | Decomplementation with cobra venom factor prolongs survival of xenografted islets in a rat to mouse model | |
AU3980595A (en) | Composition containing pooled transferrins as an active principle for the induction of immune tolerance against antigens | |
Glaser et al. | Inhibitory effect of α-globulin on the second set allograft reaction | |
Lee et al. | The effect of lyophilization on graft acceptance in experimental xenotransplantation using porcine cornea | |
Manez et al. | Neutralization of anti-aGalactosyl antibodies without immunosuppression prevents hyperacute rejection but not acute vascular rejection of pig organs transplanted into baboons |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Change of ownership |
Owner name: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH Free format text: FORMER OWNER(S): BIOSCIENCE 2002 LLC |
|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20100415 |